Cichoriin 是一种具有口服活性的香豆素糖苷,具有广泛的生物活性:它对 α-淀粉酶、α-葡萄糖苷酶、胰脂肪酶和 DPP-IV 均有抑制活性,IC50 分别为 5.76、2.94、16.83 和 9.16 μg/mL;通过激活 AMPK 信号通路,显著改善小鼠抗代谢功能障碍相关脂肪性肝炎 (MASH);上调脂肪组织中 PPAR-γ,缓解大鼠肥胖及相关心肾损伤;通过抑制 P2Y₁₄R(IC₅₀ = 8.47 nM),阻断尿酸钠晶体诱导的 NLRP3 炎症小体激活和细胞焦亡 (pyroptosis);并在计算机虚拟筛选中发现与 SARS-CoV-2 具有良好的结合能力。
产品编号: MS-N00652 纯度: 99.9% CAS No.: 531-58-8 分子式: C15H16O9 分子量: 340.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Cichoriin 是一种具有口服活性的香豆素糖苷,具有广泛的生物活性:它对 α-淀粉酶、α-葡萄糖苷酶、胰脂肪酶和 DPP-IV 均有抑制活性,IC50 分别为 5.76、2.94、16.83 和 9.16 μg/mL;通过激活 AMPK 信号通路,显著改善小鼠抗代谢功能障碍相关脂肪性肝炎 (MASH);上调脂肪组织中 PPAR-γ,缓解大鼠肥胖及相关心肾损伤;通过抑制 P2Y₁₄R(IC₅₀ = 8.47 nM),阻断尿酸钠晶体诱导的 NLRP3 炎症小体激活和细胞焦亡 (pyroptosis);并在计算机虚拟筛选中发现与 SARS-CoV-2 具有良好的结合能力。

生物实验数据

生物活性 Cichoriin is an orally active coumarin glycoside with a broad spectrum of biological activities: it inhibits α-amylase, α-glucosidase, pancreatic lipase, and DPP-IV with IC50 values of 5.76, 2.94, 16.83, and 9.16 μg/mL, respectively; it significantly ameliorates metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway; it upregulates PPAR-γ in adipose tissue to alleviate obesity and related cardiorenal injury in rats; it blocks sodium urate crystal-induced NLRP3 inflammasome activation and pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM); and it has been found by in silico virtual screening to exhibit good binding affinity to SARS-CoV-2.
IC50 & Target

PPAR-γ

 

DPP-4

 

GLUT4

 

NLRP3 inflammasome

 

P2Y14 Receptor

 

体外研究
(In Vitro)

Cichoriin 对多种糖尿病和心血管靶点表现出良好的结合亲和力,包括 α-淀粉酶、α-葡萄糖苷酶、DPP-IV、PPARγ、AMPK、GLUT-4、ACE 和 NF-κB,结合能范围为 -6.8 至 -9.8 kcal/mol。
Cichoriin (25-50 μM; 24 h) 可呈剂量依赖性降低游离脂肪酸 (FFA) 诱导的 HepG2 细胞、AML12 细胞及原代小鼠肝细胞内脂质堆积。
Cichoriin (25-50 μM; 24 h) 可降低 FFA 诱导的 AML12 小鼠肝细胞中的活性氧水平。
Cichoriin (50 μM; 24 h) 通过提高 AMPKα 和 ACC 的磷酸化水平激活 AMPK 通路,并在游离脂肪酸 (FFA) 处理的原代小鼠肝细胞中上调 CPT-1A 的表达。
Cichoriin (50 μM; 24 h) 可通过调控经 FFA 处理的原代小鼠肝细胞旁分泌信号,在间接共培养体系中抑制肝星状细胞 (HSC) 的迁移与活化 (降低 Col I 和 α-SMA 的表达)。
Cichoriin (25-50 μM; 24 h) 抑制脂毒性原代小鼠肝细胞分泌 PDGF-AA。
Cichoriin 对游离脂肪酸 (FFA) 处理的原代小鼠肝细胞的降脂、抗炎及 PDGF-AA 抑制作用,以及对共培养肝星状细胞 (HSCs) 的抗纤维化作用,均依赖于 AMPK 的激活。
Cichoriin (50-200 μM; 24 h) 在分化的 THP-1 巨噬细胞中显著抑制尿酸钠晶体诱导的 IL-1β 和 IL-18 的释放和 NLRP3、Caspase-1、GSDMD 和 ASC 的蛋白表达量。
Cichorin (50-200 μM; 24 h) 有效抑制了尿酸钠晶体驱动的巨噬细胞焦亡。

Western Blot Analysis

Cell Line: Primary mouse hepatocytes (with FFA-induced lipotoxicity)
Concentration: 50 μM
Incubation Time: 24 h (concurrent with FFA treatment)
Result: Significantly increased phosphorylation levels of AMPKα and ACC compared to FFA-only treated cells.
Upregulated CPT-1A protein expression compared to FFA-only treated cells.

Cell Migration Assay

Cell Line: Indirect Transwell co-culture of primary mouse hepatocytes and primary mouse hepatic stellate cells (HSCs) (with FFA-induced hepatocyte lipotoxicity)
Concentration: 50 μM
Incubation Time: 24 h (incubation with hepatocytes, prior to co-culture)
Result: Significantly inhibited HSC migration (reduced wound closure rate) compared to FFA-only treated hepatocytes.
Downregulated protein expression of collagen I (Col I) and alpha-smooth muscle actin (α-SMA) in co-cultured HSCs compared to FFA-only treated hepatocytes.

ELISA Assay

Cell Line: Primary mouse hepatocytes (with FFA-induced lipotoxicity)
Concentration: 25 and 50 μM
Incubation Time: 24 h
Result: Reduced FFA-induced PDGF-AA secretion from primary mouse hepatocytes compared to FFA-only treated hepatocytes.

ELISA Assay

Cell Line: THP-1 macrophages
Concentration: 25, 100 and 200 μM
Incubation Time: Pre-treatment for 1 hour, followed by stimulation with sodium urate crystals for 23 hours
Result: Significantly inhibited the release of IL-1β and IL-18.

Western Blot Analysis

Cell Line: THP-1 macrophages
Concentration: 25, 100 and 200 μM
Incubation Time: Pre-treatment for 1 hour, followed by stimulation with sodium urate crystals for 23 hours
Result: Significantly inhibited the protein expression levels of NLRP3, Caspase-1, GSDMD and ASC.
体内研究
(In Vivo)

Cichoriin (50-100 mg/kg;口服;每日;4 周) 可呈剂量依赖性缓解大鼠高脂饮食诱导的肥胖及相关代谢、氧化和组织病理学功能障碍。
Cichoriin (100-200 mg/kg/天;灌胃;每日给药;持续 6 周) 可通过激活 AMPK 通路,呈剂量依赖性地缓解雄性 C57BL/6J 小鼠中 GAN 饮食诱导的 MASH 及相关肝纤维化。

Animal Model: Wistar (male, 100-150 g initial weight, high-fat diet-induced obesity)
Dosage: 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Reduced body-weight gain to 142 g, BMI to 0.58 g/cm2, liver weight to 7.0 g, visceral fat weight to 4.7 g.
Improved serum lipid profile to total cholesterol 125 mg/dL, triglycerides 48 mg/dL, low-density lipoprotein cholesterol 93 mg/dL, high-density lipoprotein cholesterol 23 mg/dL, LDL-C/HDL-C ratio 4.2.
Lowered hepatic malondialdehyde to 107.2 nmol/g tissue, renal malondialdehyde to 78.4 nmol/g tissue, and increased hepatic reduced glutathione to 271 mg/g tissue, renal reduced glutathione to 286 mg/g tissue.
Upregulated peroxisome proliferator-activated receptor gamma mRNA and protein expression in adipose tissue.
Showed moderate improvement in heart, kidney, and liver tissue architecture with reduced tissue damage compared to HFD controls.
Reduced body-weight gain to 123 g, BMI to 0.55 g/cm2, liver weight to 6.7 g, kidney weight to 1.2 g, heart weight to 0.9 g, visceral fat weight to 3.1 g.
Improved serum lipid profile to total cholesterol 85 mg/dL, triglycerides 40 mg/dL, low-density lipoprotein cholesterol 44 mg/dL, high-density lipoprotein cholesterol 33 mg/dL, LDL-C/HDL-C ratio 1.4.
Normalized serum alanine transaminase, aspartate transaminase, urea, creatinine, and creatine kinase MB levels to near-control values.
Lowered hepatic malondialdehyde to 96.9 nmol/g tissue, renal malondialdehyde to 64.3 nmol/g tissue, and increased hepatic reduced glutathione to 325 mg/g tissue, renal reduced glutathione to 339 mg/g tissue.
Upregulated peroxisome proliferator-activated receptor gamma mRNA and protein expression in adipose tissue to levels comparable to the atorvastatin control.
Showed marked improvement in heart, kidney, and liver tissue architecture with minimal residual damage compared to HFD controls.
Animal Model: C57BL/6J (male, 8-10 weeks old, 20-25 g, GAN diet-induced MASH)
Dosage: 100 mg/kg/day; 200 mg/kg/day
Administration: oral gavage; daily; 6 weeks
Result: Significantly reduced body weight, liver index, and blood glucose levels in a dose-dependent manner.
Decreased serum levels of AST, ALT, LDH, AKP, TC, TG, LDL-C, and NEFA, while increased HDL-C levels.
Attenuated hepatic steatosis, inflammation scores, and NAFLD Activity Score (NAS), with reduced liver lipid content (Oil Red O staining area, hepatic TC, TG).
Lowered hepatic AST, ALT, and LDH levels.
Reduced liver fibrosis, as shown by decreased Masson’s trichrome staining area, hepatic hydroxyproline levels, liver Ishak score, and serum fibrosis biomarkers (HA, LN, Col IV, Pro III).
Dose-dependently suppressed mRNA expression of fibrosis-related genes (Col3a1, Col1a1, Acta2, Tgfb1), reduced Smad2 and Smad4 staining intensity, and downregulated protein expression of α-SMA, TGF-β1, Col III, and Col I.
Decreased hepatic F4/80-positive macrophage density, upregulated hepatic SOD, GSH, and CAT levels, and reduced hepatic MDA content.
Lowered hepatic levels of TNF-α, IL-6, and IL-1β, with downregulated protein levels of p-IKKβ and p-NF-κB p65, and upregulated IκBα.
Enhanced phosphorylation of AMPK (Thr172) and ACC (Ser79) at 200 mg/kg dose, increasing p-AMPK/total AMPK and p-ACC/total ACC ratios.
Reversed GAN diet-induced upregulation of pro-inflammatory factors, fibrogenic markers, and lipogenic enzymes, while restored expression of fatty acid β-oxidation and insulin signaling proteins at 200 mg/kg dose.
性状 固体
颜色 White to off-white

化学信息

分子量 340.28
分子式 C15H16O9
CAS No. 531-58-8

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (29.39 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.88 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (293.88 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.9388 mL14.6938 mL29.3876 mL73.4689 mL
5 mM0.5878 mL2.9388 mL5.8775 mL14.6938 mL
10 mM0.2939 mL1.4694 mL2.9388 mL7.3469 mL
15 mM0.1959 mL0.9796 mL1.9592 mL4.8979 mL
20 mM0.1469 mL0.7347 mL1.4694 mL3.6734 mL
25 mM0.1176 mL0.5878 mL1.1755 mL2.9388 mL
30 mM0.0980 mL0.4898 mL0.9796 mL2.4490 mL
40 mM0.0735 mL0.3673 mL0.7347 mL1.8367 mL
50 mM0.0588 mL0.2939 mL0.5878 mL1.4694 mL
60 mM0.0490 mL0.2449 mL0.4898 mL1.2245 mL
80 mM0.0367 mL0.1837 mL0.3673 mL0.9184 mL
100 mM0.0294 mL0.1469 mL0.2939 mL0.7347 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Cichoriin 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础